Skip to main content

MiR-206 regulates the progression of osteoporosis via targeting HDAC4

Abstract

Background

More and more studies have confirmed that miRNAs play an important role in maintaining bone remodeling and bone metabolism. This study investigated the expression level of miR-206 in the serum of osteoporosis (OP) patients and explored the effect and mechanism of miR-206 on the occurrence and development of osteoporosis.

Methods

120 postmenopausal women were recruited, including 63 cases with OP and 57 women without OP. The levels of miR-206 were determined by qRT-PCR technology. Spearman correlation coefficient was used to evaluate the correlation of miR-206 with bone mineral density (BMD). An ROC curve was used to evaluate the diagnostic value of miR-206 in osteoporosis. The effects of miR-206 on cell proliferation and cell apoptosis of hFOBs were measured by CCK-8 assay and flow cytometry, respectively. Luciferase reporter gene assay was used to confirm the interaction of miR-206 and the 3′UTR of HDAC4.

Results

Serum miR-206 had low expression level in osteoporosis patient group compared with control group. The expression level of serum miR-206 had diagnostic value for osteoporosis, and the serum miR-206 levels were positively correlated with BMD. The down-regulated miR-206 could inhibit cell proliferation and promote cell apoptosis. Luciferase analysis indicated that HDAC4 was the target gene of miR-206.

Conclusions

MiR-206 could be used as a new potential diagnostic biomarker for osteoporosis, and in in vitro cell experiments, miR-206 may regulate osteoblast cell proliferation and apoptosis by targeting HDAC4.

Introduction

Osteoporosis (OP) is currently the most common bone disease recognized in the world. It is characterized by decreased bone mass, decreased bone strength, and bone tissue microstructure degradation [1]. The bone mass of a healthy adult reaches its peak during puberty and continues until the next bone remodeling cycle begins. The bones in the human body are constantly undergoing bone remodeling throughout their lives, which is the process of bone resorption by osteoclasts to damaged bone tissue and new bone formation by osteoblasts [1,2,3]. OP, a systemic metabolic bone disease, whose development mechanism is that the dynamic balance of bone remodeling is broken, which makes bone resorption far more than bone formation, and then systemic bone pain and various bones complications of the disease appeared. How is this dynamic equilibrium broken? Common causes include female estrogen deficiency, decreased parathyroid hormone levels, elevated glucocorticoid levels, and abnormal growth hormone levels [4]. Studies have found that more than 50% of osteoporotic fractures in women over 50 are due to an estimated 20% loss of bone density within 5 years after menopause [5, 6]. Therefore, to explore the pathogenesis of OP and find effective ways to prevent and treat OP is the foothold that should be paid more attention to at present.

MicroRNAs are small, non-coding single-stranded RNAs that regulate gene expression by blocking protein translation. Many miRNAs regulate various pathophysiological events, including hematopoietic function [7], organogenesis [8], cell proliferation and cell apoptosis [9], and tumorigenesis and progression [10]. MiRNAs are involved in bone cell differentiation, bone development, and bone disease. In the past few decades, a large number of miRNAs have been clearly found to be involved in the regulation of bone remodeling, including bone resorption and bone formation. The role of miRNAs in the growth and differentiation of osteoclasts and osteoblasts has been extensively studied [11]. Cao et al. conducted a preliminary study on miRNA biomarkers in circulating monocytes of patients with postmenopausal OP and found that the expression of miR-422a was down-regulated in the serum of OP patients, thus confirmed that miR-422a was a specific cell marker of postmenopausal OP [12]. MiR-206, previously viewed as a muscle-specific miRNA, has been reported to play a key role in osteosarcoma through regulating osteosarcoma cell viability and apoptosis [13]. Inose et al. reported that miR-206 regulated osteoblast differentiation by targeting connexin 43 (Cx43) in C2C12 cells [14]. Moreover, in the current study, miR-206 is identified to be significantly down-regulated in osteoporosis mouse model, indicating its potential role in the development of OP [15]. But the role and clinical value of miR-206 in OP is poorly understood.

Therefore, in the present study, in order to explore the clinical value of miR-206 in OP, the expression levels of serum miR-206 in postmenopausal OP patients and non-OP patients were measured, and the diagnostic value of miR-206 in OP was evaluated. In addition, its role in osteoblast cell proliferation and apoptosis was further explored in vitro.

Materials and methods

Study population and sample collection

This study protocol has been approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Harbin Medical University, and the recruited personnel have signed written informed consent.

A total of 120 postmenopausal women were recruited, including 63 postmenopausal women with OP as OP patient group and 57 postmenopausal women without OP as control group. Participants were selected based on the following conditions: (1) consent to participate in the study and informed consent, (2) no history of hormone replacement therapy, (3) no chronic malignant disease or genetic disease, and (4) no history of smoking or drinking.

Cell culture

The main function of Human fetal osteoblast cell lines (hFOBs) is to produce bone matrix, secrete I collagen and non-collagen, and regulate bone absorption of osteoclast. The decrease of hFOBs viability caused by various factors can cause osteopenia and eventually lead to the occurrence of OP. Increasing the activity of hFOBs is one of the keys to prevent and treat metabolic bone diseases. Therefore, hFOBs was selected as the subject cell in this study [16, 17]. hFOBs (Chinese Academy of Medical Sciences, China) were cultured in Dulbecco Modified Eagle Medium (DMEM)/HAM F12 (Sigma-Aldrich, Dorset, UK) supplemented with 10% fetal bovine serum (FBS, Gibco), 1% triple antibiotic (penicillin, streptomycin, and amphotericin-B) (Solarbio), 0.6 mg/mL geneticin, and 2 mM l-glutamine (Gibco) at 37 ℃ temperature in a 5% CO2 and a 95% humidified atmosphere for 2 days of incubation.

Cell transfection

MiR-206 inhibitor and a negative control (miR-NC) were purchased from Shanghai GenePharma Company. hFOBs were seeded onto 6-well plate at a density of 1 × 105 cells per well, and after incubation for 24 h, cells were transfected with miR-NC and miR-206 inhibitor using lipofectamine2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) to mimic OP condition by regulating miR-206 expression according to product specification.

Total RNA extraction and qRT-PCR

Total RNA was isolated by TRIzol reagent (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer’s instructions. RNA was then reverse transcribed into cDNA by the PrimeScript RT Reagent Kit (TaKaRa, Dalian, China). The qRT-PCR was conducted by SYBR Green Real-time PCR Master Mix (Toyobo Co. Ltd., Osaka, Japan) with the following conditions: 95 °C for 5 min and followed by 30 cycles of 95 °C for 30 s, 58–61 °C for 30 s, and 72 °C for 2 min. The U6 was used as an internal control, and the relative gene expression levels were calculated by the 2−ΔΔCt method.

Cell proliferation assay

Cell Counting Kit-8 (CCK-8) assay is based on the principle that mitochondrial dehydrogenases oxidize WST-8 to a formazan dye product. Cell proliferation of 24 h, 48 h, and 72 h was detected using the CCK-8 kit (Dojindo, Japan) according to the instructions. Briefly, cells were seeded in a density of 5 × 104 cells/well onto the 96-well plates and cultured completely adherent to the wall, and then CCK-8 was added into the cells and incubated at 37 ℃ for 2 h. The absorbance was measured at 450 nm using a microplate reader (Thermo Fisher Scientific).

Cell apoptosis assay

An Annexin V-FITC Apoptosis Detection kit (Keygen Biotechnology) was used for the quantitative analysis of the cell apoptosis using flow cytometry. Cells were seeded onto a 6-well plate at a density of 1 × 106 cells per well. After 24 h of incubation, cells were harvest and washed with cold PBS buffer for 3 times. Next, cells were re-suspended with 0.5 mL of cold PBS to make the cell density is greater than 1 × 105 cells, and then, 5 μL of Annexin V-FITC and 1 μL of PI staining solution were added into the cell suspension for another 15 min of incubation in the darkness. Finally, the cell apoptosis rates were measured by a flow cytometer (FACSCanto II flow cytometer, BD Biosciences).

Luciferase reporter gene assay

The online program Target-scan 7.0 predicted that there was a binding site between miR-206 and HDAC4 3′UTR, so HDAC4 was speculated to be the potential target gene of miR-206. Then, we selected the luciferase reporter gene assay to verify this conjecture. The 3′-UTR of HDAC4 was cloned into PGL3 luciferase reporter gene vector to build wild type (WT) and mutant type (MT) of HDAC4 3′-UTR luciferase report vectors. Then the cells were co-transfected with the WT-HDAC4 or MUT-HDAC4 and miR-206 inhibitor or miR-NC. After incubation for 48 h, the luciferase activity of each group was detected in strict accordance with the instructions of the dual-luciferase reporting system (Promega, INC., USA). The fluorescent intensity of renal cells was used as an internal reference.

Statistical analysis

All statistical analyses in this paper were employed by SPSS 21.0 software (SPSS Inc., Chicago, IL) and GraphPad Prism 7 software (GraphPad Software, Inc., USA). Data are presented as mean ± standard deviation (SD), and the differences in two groups were performed by Student’s t-test or one-way ANOVA. The Spearman correlation coefficient was used to assess the correlation between continuous variables. P-values were considered statistically significant as follows: ***P < 0.001. Each experiment was conducted in triplicate.

Results

Clinical characteristics

As shown in Table 1, there were no significant differences in age and BMI between the OP patient group (postmenopausal women with OP) and the control group (postmenopausal women without OP). It was worth noting that the value of LSBMD, FNBMD, and THBMD in OP patient group was significantly lower than that in the control group (P < 0.001).

Table 1 Clinical data of the study population

Expression level of miR-206 in OP patients

The serum expression levels of miR-206 in all participants were determined by qRT-PCR, and the results are shown in Fig. 1. The serum expression level of miR-206 in OP patient group was significantly lower than in the control group (P < 0.001), which suggested that the expression of miR-206 may be involved in bone formation and affect the progression of OP.

Fig. 1
figure1

The expression level of miR-206 in the serum of OP patient group (postmenopausal women with OP) and control group (postmenopausal women without OP). The OP patient group had significantly low expression level of miR-206 (P < 0.001)

Correlation analysis of miR-206 with LSBMD, FNBMD, and THBMD in OP patients

In the present study, the correlation of miR-206 expression with LSBMD, FNBMD, and THBMD was investigated and the results are shown in Fig. 2. The results showed that serum miR-206 in OP patients was positively correlated with LSBMD (r = 0.638, P < 0.001), FNBMD (r = 0.738, P < 0.001), and THBMD (r = 0.779, P < 0.001). The above results further indicated that miR-206 played an important role in the occurrence and progression of OP.

Fig. 2
figure2

The correlation of serum miR-206 level with LSBMD (a), FNBMD (b) and THBMD (c) in OP patient group. Serum miR-206 levels were positively correlated with LSBMD (r = 0.638, P < 0.001), FNBMD (r = 0.738, P < 0.001), and THBMD (r = 0.779, P < 0.001) in OP patients

ROC curve analysis

The ROC curve was established according to the expression level of serum miR-206 in the OP patient group and the control group. From the ROC curve in Fig. 3, the following conclusions can be drawn: the area under the curve (AUC) is 0.860, the sensitivity is 73.0%, and the specificity is 87.7%. Therefore, it can be inferred that the expression level of serum miR-206 can be used to distinguish patients with OP and without OP.

Fig. 3
figure3

An ROC curve was established to evaluate the diagnostic ability of serum miR-206 in OP. The area under the curve (AUC) for miR-206 was 0.860, with a sensitivity of 73.0% and specificity of 87.7% at the cutoff value of 0.797

Effects of miR-206 on hFOBs cell proliferation and apoptosis

Figure 4a shows the expression level of miR-206 in the cells after transfection with miR-206 inhibitor and miR-NC. It can be seen that the expression level of miR-206 in the miR-206 inhibitor group has been reduced significantly compared with the control group (P < 0.001), which can be used to simulate the low expression state of miR-206 in the serum of OP patients. The result of cell proliferation assay is shown in Fig. 4b; cell viability decreased significantly with the extension of cell incubation time after the down-regulation of miR-206 expression in comparison with the control group (P < 0.001). Cell apoptosis results showed that the apoptosis rates of miR-206 inhibitor group were significantly increased compared with the control group (Fig. 4c, P < 0.001). Based on the above experimental results, we have reason to believe that the down-regulated expression of miR-206 is not only detrimental to the cell viability of hFOBs but also promotes cell apoptosis.

Fig. 4
figure4

The relative expression level of miR-206 in cells transfected with different reagents and the effect of miR-206 on the proliferation and apoptosis of hFOBs. a Transfected with miR-206 inhibitor significantly decreased the expression level of miR-206 in hFOBs compared with other cell groups (P < 0.001). b The cell viability of hFOBs was significantly decreased in transfection with miR-206 inhibitor compared with other groups (P < 0.001). c The cell apoptosis of hFOBs was significantly increased in transfection with miR-206 inhibitor compared with other groups (P < 0.001)

MiR-206 directly targets HDAC4 in hFOBs cells

Target scan analysis results showed the binding sites of miR-206 in HDAC4 3′-UTR that are shown in Fig. 5a. Luciferase reporter gene assay results showed that transfected with miR-206 inhibitor significantly increased the luciferase activity in cells transfected with wide-type 3′-UTR of HDAC4 (P < 0.001). In addition, the transfection of miR-NC or miR-206 inhibitor did not affect the luciferase intensity of the MUT group.

Fig. 5
figure5

MiR-206 directly targets HDAC4 in hFOBs. a The binding site of miR-206 in HDAC4. b Cells transfected with miR-206 inhibitor significantly increased its luciferase activity. Besides, the luciferin activity of the mutant-type group was not affected by the transfection of miR-NC or miR-206 inhibitor (P > 0.05)

Discussion

Postmenopausal osteoporosis (PMOP) is one of the major manifestations of OP. In general, the dual processes of bone resorption and bone formation are tightly coupled to maintain a stable bone homeostasis state [18, 19]. For PMOP, postmenopausal women may experience a certain amount of bone loss, resulting in increased bone resorption and reduced bone formation. However, the exact mechanism behind PMOP is still unclear. Although osteoblasts and osteocyte apoptosis have been shown to play an important role in PMOP, there are still many issues that need to be explored and investigated [20, 21]. Osteoporosis-related fractures/brittleness and osteoarthritis are age-related diseases that have been increasing in incidence and prevalence in recent years due to an aging population [22, 23]. OP as a part of the natural aging process of the human body, its pathogenesis remains to be clarified. Current therapies, including hormone replacement therapy and immunotherapy, are associated with the risk of side effects. Therefore, it is vital to further understand the pathophysiological mechanism of OP for the development of new therapeutic methods.

MiR-206 is a member of the so-called myomiR family (i.e., miR-1, miR-133, and miR-206) and is widely believed to be a specific positive regulator of skeletal muscle differentiation [24, 25]. In this study, through the detection of the expression level of serum miR-206 in 120 postmenopausal women, we found that the expression level of serum miR-206 in the OP patient group was significantly lower than that in the control group, suggesting that miR-206 may play a certain role in the OP of postmenopausal women. In addition, the relevant indicators of OP, such as bone mineral density (BMD), were tested and the correlation between the expression level of miR-206 in serum and BMD was investigated. Finally, it was found that the expression level of miR-206 in OP patients was positively correlated with BMD, which further explained the correlation between miR-206 and OP. In the study of Elatta et al., it was found that serum miR-206 expression levels were significantly higher in patients with rheumatoid arthritis (RA) than in healthy controls (P < 0.001). At the same time, the serum inflammatory factors (IL-16 and IL-17) were significantly increased in RA patient group. Their study suggested the importance of miR-206 expression in RA patients as a potential new biomarker for bone loss/deformity, and revealed its synergistic role with pro-inflammatory cytokines, such as IL-16 and IL-17, in RA bone metabolism [26]. In another study, it was found that bone marrow mesenchymal stem cells (BMSCs) were isolated from ovariectomy (OVX) mice and normal mice for gene detection to screen out microRNAs that are most likely to participate in the mechanism of OP, including miR-206 [15]. All the above results supported our speculation on the role of miR-206 in the occurrence and development of OP. Moreover, through ROC curve analysis, we believed that miR-206 had the ability to distinguish postmenopausal women with OP from those without OP.

Dysfunction of osteoblasts is the most fundamental cause of OP. Therefore, it is necessary to explore the related functions of osteoblasts in revealing the mechanism of OP [27]. Subsequently, in this study, we investigated the effects of miR-206 on the proliferation and apoptosis of hFOBs. Cell transfection was used to down-regulate the expression of miR-206 in hFOBs, and the survival rate of cells transfected with miR-206-inhibitor was significantly reduced compared with untreated cells. In addition, the results of cell apoptosis assay were consistent with the results of cell proliferation inhibition assay, that is, after the expression of miR-206 was down-regulated, the cell apoptosis rate was significantly increased. The above results both indicated that when the expression level of miR-206 in hFOBs was low, it was not conducive to the proliferation of hFOBs and could lead to proliferation inhibition and apoptosis promotion. This result was also supported the observation about the low expression of miR-206 in serum of OP patients.

Studies have shown that the interaction of HDAC4, H3K9ac, and H3K27ac in OP is essential to maintain mineralized matrix synthesis and osteoclast regulation of the production of chemokines, which can protect bone tissue from the development of OP mediated by glucocorticoid overdose or estrogen deficiency [28]. Chen et al. found in their study that miR-19A-3P promoted the osteogenic differentiation of hMSCs by targeting HDAC4 and delayed the progression of osteoporosis [29]. At the end of this study, we preliminarily identified Histone Deacetylase 4 (HDAC4) as a potential target gene of miR-206 based on target scanning database. Based on the above findings, we selected luciferase reporter gene assay to determine whether HDAC4 is the target of miR-206. The results showed that luciferase activity was enhanced when miR-206 was down-regulated, suggesting that HDAC4 is the target gene of miR-206. Consistently, in a study of chronic constriction injury, HDAC4 has been proven to be the target gene of miR-206 [30].

In conclusion, this study confirmed that miR-206 was low expressed in serum of postmenopausal women with OP and had diagnostic value for OP. MiR-206 may be involved in the occurrence and development of OP by targeting HDAC4. The above results provided a basis for further elucidating the relationship between miR-206 and the occurrence and development of OP in postmenopausal women.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

BMD:

Bone mineral density

OP:

Osteoporosis

hFOBs:

Human fetal osteoblast cell lines

DMEM:

Dulbecco Modified Eagle Medium

CCK-8:

Cell Counting Kit-8

WT:

Wild type

MT:

Mutant type

SD:

Standard deviation

AUC:

Area under the curve

PMOP:

Postmenopausal osteoporosis

RA:

Rheumatoid arthritis

BMSCs:

Bone marrow mesenchymal stem cells

OVX:

Ovariectomy

HDAC4:

Histone Deacetylase 4

References

  1. 1.

    Rossi LMM, Copes RM, Dal Osto LC, Flores C, Comim FV, Premaor MO. Factors related with osteoporosis treatment in postmenopausal women. Medicine (Baltimore). 2018;97:e11524.

    Article  Google Scholar 

  2. 2.

    Coughlan T, Dockery F. Osteoporosis and fracture risk in older people. Clin Med. 2014;14:187–91.

    Article  Google Scholar 

  3. 3.

    Klahan S, Kuo CN, Chien SC, Lin YW, Lin CY, Lin CH, et al. Osteoporosis increases subsequent risk of gallstone: a nationwide population-based cohort study in Taiwan. BMC Gastroenterol. 2014;14:192.

    Article  Google Scholar 

  4. 4.

    Chen X, Zhi X, Cao L, Weng W, Pan P, Hu H, et al. Matrine derivate MASM uncovers a novel function for ribosomal protein S5 in osteoclastogenesis and postmenopausal osteoporosis. Cell Death Dis. 2017;8:e3037.

    Article  Google Scholar 

  5. 5.

    Sanders S, Geraci SA. Osteoporosis in postmenopausal women: considerations in prevention and treatment: (women’s health series). South Med J. 2013;106:698–706.

    CAS  Article  Google Scholar 

  6. 6.

    Miller PD. Management of severe osteoporosis. Expert Opin Pharmacother. 2016;17:473–88.

    CAS  Article  Google Scholar 

  7. 7.

    Kim M, Civin CI, Kingsbury TJ. MicroRNAs as regulators and effectors of hematopoietic transcription factors. Wiley Interdiscip Rev RNA. 2019;10:e1537.

    Article  Google Scholar 

  8. 8.

    Hayashi T, Hoffman MP. Exosomal microRNA communication between tissues during organogenesis. RNA Biol. 2017;14:1683–9.

    Article  Google Scholar 

  9. 9.

    Mens MMJ, Ghanbari M. Cell cycle regulation of stem cells by microRNAs. Stem Cell Rev Rep. 2018;14:309–22.

    CAS  Article  Google Scholar 

  10. 10.

    Bellavia D, Salamanna F, Raimondi L, De Luca A, Carina V, Costa V, et al. Deregulated miRNAs in osteoporosis: effects in bone metastasis. Cell Mol Life Sci. 2019;76:3723–44.

    CAS  Article  Google Scholar 

  11. 11.

    Bellavia D, De Luca A, Carina V, Costa V, Raimondi L, Salamanna F, et al. Deregulated miRNAs in bone health: epigenetic roles in osteoporosis. Bone. 2019;122:52–75.

    CAS  Article  Google Scholar 

  12. 12.

    Cao Z, Moore BT, Wang Y, Peng XH, Lappe JM, Recker RR, et al. MiR-422a as a potential cellular microRNA biomarker for postmenopausal osteoporosis. PLoS ONE. 2014;9:e97098.

    Article  Google Scholar 

  13. 13.

    Bao YP, Yi Y, Peng LL, Fang J, Liu KB, Li WZ, et al. Roles of microRNA-206 in osteosarcoma pathogenesis and progression. Asian Pac J Cancer Prev. 2013;14:3751–5.

    Article  Google Scholar 

  14. 14.

    Inose H, Ochi H, Kimura A, Fujita K, Xu R, Sato S, et al. A microRNA regulatory mechanism of osteoblast differentiation. Proc Natl Acad Sci USA. 2009;106:20794–9.

    CAS  Article  Google Scholar 

  15. 15.

    Wang H, Zhou K, Xiao F, Huang Z, Xu J, Chen G, et al. Identification of circRNA-associated ceRNA network in BMSCs of OVX models for postmenopausal osteoporosis. Sci Rep. 2020;10:10896.

    CAS  Article  Google Scholar 

  16. 16.

    Li Y, Liang W, Li X, Gao B, Gan H, Yin L, et al. Effect of serum from postmenopausal women with osteoporosis exhibiting the Kidney-Yang deficiency pattern on bone formation in an hFOB 1.19 human osteoblastic cell line. Exp Ther Med. 2015;10:1089–95.

    CAS  Article  Google Scholar 

  17. 17.

    di Giacomo V, Cataldi A, Sancilio S. Biological factors, metals, and biomaterials regulating osteogenesis through autophagy. Int J Mol Sci. 2020;21:2789.

    Article  Google Scholar 

  18. 18.

    Cui H, Zhu Y, Jiang D. The RIP1–RIP3 complex mediates osteocyte necroptosis after ovariectomy in rats. PLoS ONE. 2016;11:e0150805.

    Article  Google Scholar 

  19. 19.

    Emerton KB, Hu B, Woo AA, Sinofsky A, Hernandez C, Majeska RJ, et al. Osteocyte apoptosis and control of bone resorption following ovariectomy in mice. Bone. 2010;46:577–83.

    CAS  Article  Google Scholar 

  20. 20.

    Bottani M, Banfi G, Lombardi G. Perspectives on miRNAs as epigenetic markers in osteoporosis and bone fracture risk: a step forward in personalized diagnosis. Front Genet. 2019;10:1044.

    CAS  Article  Google Scholar 

  21. 21.

    Piper PK Jr, Gruntmanis U. Management of osteoporosis in the aging male: focus on zoledronic acid. Clin Interv Aging. 2009;4:289–303.

    CAS  Article  Google Scholar 

  22. 22.

    Tang P, Xiong Q, Ge W, Zhang L. The role of microRNAs in osteoclasts and osteoporosis. RNA Biol. 2014;11:1355–63.

    Article  Google Scholar 

  23. 23.

    Ge DW, Wang WW, Chen HT, Yang L, Cao XJ. Functions of microRNAs in osteoporosis. Eur Rev Med Pharmacol Sci. 2017;21:4784–9.

    PubMed  Google Scholar 

  24. 24.

    Townley-Tilson WH, Callis TE, Wang D. MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol. 2010;42:1252–5.

    CAS  Article  Google Scholar 

  25. 25.

    Smith ML, Lopez MF, Archer KJ, Wolen AR, Becker HC, Miles MF. Time-course analysis of brain regional expression network responses to chronic intermittent ethanol and withdrawal: implications for mechanisms underlying excessive ethanol consumption. PLoS ONE. 2016;11:e0146257.

    Article  Google Scholar 

  26. 26.

    ElAtta AA, Ali Y, Bassyouni I, Talaat R. Correlation of myomir-206 and proinflammatory cytokines (IL-16 and IL-17) in patients with rheumatoid arthritis. Reumatologia. 2019;57:72–7.

    Article  Google Scholar 

  27. 27.

    Brennan TA, Egan KP, Lindborg CM, Chen Q, Sweetwyne MT, Hankenson KD, et al. Mouse models of telomere dysfunction phenocopy skeletal changes found in human age-related osteoporosis. Dis Model Mech. 2014;7:583–92.

    CAS  Article  Google Scholar 

  28. 28.

    Chen YS, Lian WS, Kuo CW, Ke HJ, Wang SY, Kuo PC, et al. Epigenetic regulation of skeletal tissue integrity and osteoporosis development. Int J Mol Sci. 2020;21:4923.

    CAS  Article  Google Scholar 

  29. 29.

    Chen R, Qiu H, Tong Y, Liao F, Hu X, Qiu Y, et al. MiRNA-19a-3p alleviates the progression of osteoporosis by targeting HDAC4 to promote the osteogenic differentiation of hMSCs. Biochem Biophys Res Commun. 2019;516:666–72.

    CAS  Article  Google Scholar 

  30. 30.

    Wen J, He T, Qi F, Chen H. MiR-206-3p alleviates chronic constriction injury-induced neuropathic pain through targeting HDAC4. Exp Anim. 2019;68:213–20.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Affiliations

Authors

Contributions

ZL, ZB, and JS contributions to conception and design of this study. ZL, DW, XW, and JZ carried out the study and analyzed and interpreted the data. All the authors drafted the manuscript; ZB and JS revised it critically for important intellectual content. All the authors read and approved the final manuscript.

Corresponding authors

Correspondence to Jiabing Sun or Zhenggang Bi.

Ethics declarations

Ethics approval and consent to participate

This study protocol has been approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Harbin Medical University.

Consent for publication

The recruited personnel have signed written informed consent.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lu, Z., Wang, D., Wang, X. et al. MiR-206 regulates the progression of osteoporosis via targeting HDAC4. Eur J Med Res 26, 8 (2021). https://doi.org/10.1186/s40001-021-00480-3

Download citation

Keywords

  • MiR-206
  • Osteoporosis
  • Cell proliferation
  • Cell apoptosis